Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer

A population of modified human monocytes comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain and an intracellular domain of a stimulatory and/or co-stimulatory molecule, wherein >75% of the modified human monocytes in the population of cells express the CAR or wherein the modified human monocytes in the population of cells are genetically modified to stably express the CAR, and wherein the modified human monocytes replicate in vivo resulting in long-term persistence that can lead to sustained tumor control.

A pharmaceutical composition comprising the population of modified human monocytes of claim 51 and a pharmaceutically acceptable carrier.

A method for stimulating an immune response to a target tumor cell or tumor tissue in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the population of modified human monocytes of claim 51.

A method of modifying a population of human monocytes, comprising:

• introducing a chimeric antigen receptor (CAR) into the population of human monocytes, wherein the CAR comprises an antigen binding domain, a transmembrane domain and an intracellular domain of a stimulatory and/or co-stimulatory molecule, wherein >75% of the monocytes in the population of modified human monocytes express the CAR or wherein the modified human monocytes in the population of cells are genetically modified to stably express the CAR, and wherein the modified human monocytes replicate in vivo resulting in long-term persistence that can lead to sustained tumor control.

A pharmaceutical composition comprising:

• (a) a population of modified human macrophages and/or monocytes comprising a chimeric antigen receptor (CAR), wherein >75% of the macrophages and/or monocytes in the population of modified human macrophages and/or monocytes express the CAR or wherein the modified human macrophages and/or monocytes in the population of modified human macrophages and/or monocytes are genetically modified to stably express the CAR, and
• (b) a pharmaceutically acceptable excipient.

A method of modifying a population of human cells, comprising:

• introducing a chimeric antigen receptor (CAR) into the population of human macrophages and/or monocytes, wherein >75% of the macrophages and/or monocytes in the population of human macrophages and/or monocytes express the CAR or wherein the human macrophages and/or monocytes in the population of human macrophages and/or monocytes are genetically modified to stably express the CAR.